Αρχική World News EMA Recommends Extending Indications for Durvalumab World News EMA Recommends Extending Indications for Durvalumab Από Ogkologos - 17 Ιουλίου, 2025 823 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... 14 Μαρτίου, 2024 How to Cope With Taking Long-Term Medication 27 Ιουνίου, 2023 Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death... 31 Ιουλίου, 2023 El cáncer en mi comunidad: Cómo acceden las personas con cáncer... 12 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS Study Tackles Key Questions about Liver Transplants for People with Liver... New targeted treatments raise the bar in immunotherapy-resistant melanoma Veteran Drops To The Ground When He Hears How Much His... COVID-19 vaccine and cancer – latest updates